Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Taxable Anonymous Libre Electronic Reserves (TALER)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: A human-centred and ethical development of digital and industrial technologies
Action type: Innovation actions
Countries involved: Netherlands,Germany,Luxembourg,Belgium,France,Greece,Hungary,Switzerland
Call: Pilots for the Next Generation Internet (IA) (HORIZON-CL4-2023-HUMAN-01-CNECT, 2023)
Start date: 2023-12-01
End date: 2026-11-30
Duration (months): 36.0
Total project cost (EUR): 5328359.25
EU funding (EUR): 4508355.4
Participants: 11
Project status: SIGNED

TALER will roll out a new electronic payment system that benefits European citizens, merchants, and banks. GNU Taler is a privacy-preserving digital payment system developed by the GNU community and Taler Systems SA with additional funding from various NGI calls (NGI0 PET, NGI0 Entrust, NGI POINTER, NGI TRUST). GNU Taler offers privacy for the buyer while enforcing transparency on sellers. As a result, citizens do not suffer from surveillance when paying with GNU Taler, and States can ensure that businesses can be held accountable for their income and pay their taxes. The first vertical addressed by TALER is the financial industry. TALER will bring GNU Taler to TRL 9 by making GNU TALER available as payment system via retail banks (via GLS and MAGNET Bank). TALER counts three verticals for its go-to-market strategy. The first is the publishing sector: independent book publishers and journalists will integrate the sector with GNU Taler as a viable payment system. The e-health sector will implement GNU Taler as payment option for e-Health providers to guarantee privacy of the payer. Finally, the FLOSS ICT supply chain vertical will integrate GNU Taler in the FLOSS development ecosystem for donations and pledges. We expect TALER to have several long lasting impacts: By providing micro payments at very low overhead GNU Taler permits Internet business models to shift away from advertising revenue or subscription models, especially for online publishers, The no-risk transactions will lower transaction fees and open online payments for the underbanked population and citizens marginalized from digitalisation. Finally, easy to use, efficient and privacy-respecting commercial payments will likely impact the debate on central bank digital currencies (CBDCs) such as the Digital Euro, as central banks globally struggle to present a compelling use-case for their retail CBDC projects.

Keywords: digital payment,open source,trustworthy ict
Characterising the microbiome and mycotoxin profiles of winter wheat varieties grown under sustainable crop protection system (ToxBiome)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Netherlands,United Kingdom
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-01-01
End date: 2025-12-31
Duration (months): 24.0
Total project cost (EUR): 203464.32
EU funding (EUR): 203464.32
Participants: 2
Project status: SIGNED

During wheat colonisation, toxigenic Fusarium species produce substantial numbers of mycotoxins, which pose serious adverse health effects in human and animals. The current control strategies rely on the use of resistant varieties and synthetic fungicides. However, these control measures are not always effective. Moreover, excessive use of fungicides has led to the development of resistance in many toxigenic Fusarium species. Therefore, there is an urgent need to develop an effective and sustainable method to minimise wheat mycotoxin content. The goal of this project is to provide novel insights into the role of wheat microbiome in preventing mycotoxin contamination and to identify wheat varieties and microbes with potential to promote the suppression of mycotoxin production in wheat. Fungicide untreated winter wheat varieties will be collected from three different experimental field sites in Ireland and Northern Ireland. Then, a targeted metabolomics approach will be used to quantify 10 important mycotoxins in winter wheat samples, to identify resistant and susceptible varieties. Subsequently, DNA will be extracted from the samples and a culture-independent shotgun metagenomic high-throughput sequencing will be applied to characterise the microbiome diversity and function of wheat varieties. Robust statistical tests and bioinformatics tools will be used to analyse and compare sequences and mycotoxin level data, to identify specific microbial species and metabolic pathways that are significantly correlated with wheat varieties found resistant and susceptible to mycotoxin accumulation. Ultimately, the identification of specific wheat varieties that recruit microbiomes that can inhibit mycotoxin production opens new horizons for breeding next-generation crops depending less on fungicide input and resistant to mycotoxin contamination. This project and the planned training activities will further enhance my skills to become an independent researcher.
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test (BioFlow)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Israel
Call: ERC PROOF OF CONCEPT GRANTS2 (ERC-2022-POC2, 2022)
Start date: 2022-09-01
End date: 2024-02-29
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Immunotherapy has revolutionised clinical oncology, with the use of immune checkpoint inhibitors (ICIs). These agents are in clinical use for almost a decade, treating over 20 types of cancers. They have shown a remarkable therapeutic benefit even in patients with advanced disease. Yet, only a small proportion of patients benefit from this therapy, leaving the rest resistant, for reasons that are still not clear. While there are certain clinical biomarkers to predict ICI therapy outcome, their prevalence and prediction power is rather limited. Therefore, there is a clinical unmet need to develop more powerful biomarkers to predict response to immunotherapy. In our ongoing ERC consolidator grant we discovered a unique sub-population of neutrophils, present in peripheral blood, that predicts response to immunotherapy in a very high probability. We designated these cells as immunotherapy-responsiveness cells (IRCs). Using various mouse models, we demonstrate that the levels of circulating IRCs measured at baseline are significantly higher in responding tumours to ICI therapy. These results were confirmed in a limited number of non-small cell lung cancer (NSCLC) and melanoma patients. Hence, our aim is to further test IRC levels in clinical samples, to evaluate their predictive power for ICI therapy, and to develop a clinical liquid biopsy-based predictive biomarker using flow cytometry test. The development of clinical IRC detection based on flow cytometry (BioFlow®) can serve two markets: (1) Clinicians – enabling oncologists to easily predict response to ICI therapy, thus improving personalised immunotherapy treatment; and (2) Pharmaceutical companies - developing immunotherapies - that can use IRC detection in development stages and through clinical studies, enabling tight regulative assessment of R&D success rates. The BioFlow goal is to technically validate and develop a predictive biomarker platform for both markets that will lead to its commercialisation.
Implementation of an Integrated Care Model for Patients with Multiple Cardiometabolic and Mental Health Conditions in Sub-Saharan Africa (M-CARE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Netherlands,Denmark,Ghana,Kenya,Uganda,United Kingdom
Call: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (HORIZON-HLTH-2024-DISEASE-13, 2024)
Start date: 2025-07-01
End date: 2030-06-30
Duration (months): 60.0
Total project cost (EUR): 4000000.0
EU funding (EUR): 4000000.0
Participants: 7
Project status: SIGNED

Addressing multiple long-term conditions including non-communicable diseases (MLTC-NCDs) in fragile health systems in sub-Saharan African(SSA) demands a shift from fragmented models of care, that treat individual health issues separately to a more holistic integrated care that provides a whole-person focus. However, the feasibility and effectiveness of concurrently implementing evidence-based WHO PEN and mhGAP-IG for integrated care of NCDs and common mental health problems in real primary healthcare settings remain unexplored. In addition, the adoption and implementation of the WHO PEN and mhGAP-IG strategy has been poor in the SSA, where recent analysis found the adoption and implementation to be off-track. M-CARE project therefore aims to improve primary care for patients (aged ≥18 years) with MLTC-cardiometabolic and common mental health conditions in three SSA countries (Ghana, Kenya & Uganda) by designing, deploying, and evaluating strategies for implementing the evidence-based integrated primary care model interventions that map onto WHO PEN and mhGAP-IG for PHC, taking into account diverse socioeconomic environments of these countries. The intervention delivery will be a pragmatic trial implemented in usual primary care facilities by primary care providers through a parallel arm cluster randomized design. The trial is preceded by codesign of the integrated care with stakeholders. This multi-sectoral approach will increase the capability, opportunity to improve integrated management of patients with MLTC-cardiometabolic disease and common mental health disorders in diverse SSA environments. We anticipate that the M-CARE project will lead to 35% increase in proportion of patients with MLTC-NCDs to be engaged and retained in care for effective management within 12 months. The M-CARE project will pave the way for translation and broad scale-up implementation of the evidence-based interventions to manage patients with MLTC-NCDs in SSA and beyond.

Keywords: multiple long term chronic conditions primary health care,global health
Revolutionizing Tire Longevity: Self-Healing Polymer Coating to Prevent Punctures and Reduce Tire Waste (Healant)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Belgium
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

End-of-life tires (ELTs) present significant environmental and health challenges. Up to 12% of tires are scrapped prematurely, resulting in 3.35 million tons of waste annually, accounting for about 0.16% of global waste. These non-biodegradable tires often end up in landfills or are incinerated, releasing harmful pollutants such as 6PPD, dioxins, and PAHs, which can cause cancer and respiratory diseases. On the other hand, the production of a new car tire uses 26.5 liters of crude oil, underscoring the unsustainable use of resources. Until today, there are no solutions in the market satisfying this need of “Extended Mobility”. Our solution, 'Healant,' is a self-healing polymer layer applied to the inside of tires, enabling them to repair themselves after a puncture. Unlike current technologies that try to "seal", our innovation "heals" the puncture, restoring the tire to its original state, significantly extending its lifespan. This technology not only enhances product durability but is also fully recyclable, offering a sustainable alternative to conventional sealants which are not recyclable and add to environmental waste. We are initially targeting the automotive tire industry, with plans to expand into other sectors like 3D printing and plastic part production. The total addressable market for puncture-proof tires is estimated to be €4,75 bn by 2030. With strategic partnerships (including Henkel - #1 adhesive producer globally and Apollo Vredestein - 13th largest tire manufacturer in the world) in place, we are well-positioned to capture a significant market share. Our technology aims to reduce CO2 emissions by preventing premature tire disposal and supports a circular economy. By extending tire life, we expect to prevent 25m tires from being scrapped by 2035, saving 240.143 tonnes of CO2 emissions. We seek a €2,5m grant to finance final material formulation, regulatory compliance, and allow sales directly after completion of Accelerator.

Keywords: self healing polymers,car,bus,truck tires,lifetime extension avoidance of waste
PN6047 - a breakthrough treatment of neuropathic pain (PN6047-DOBRA)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-11-01
End date: 2027-04-30
Duration (months): 30.0
Total project cost (EUR): 3561428.57
EU funding (EUR): 2493000.0
Participants: 1
Project status: SUSPENDED

PharmNovo aims to develop novel drugs with superior clinical properties to treat patients suffering from chronic pain using knowledge and experience in drug design and G protein-coupled receptor pharmacology. Pharmnovo’s lead drug candidate is PN6047 - a completely new type of opioid drug for neuropathic pain, with a first-in-class market potential. Unlike the currently available opioid drugs which activate all opioid receptors, PN6047 is a very selective delta opioid receptor agonist (activator). Due to its unique molecular structure, PN6047 selectively activates the G protein signalling pathway while avoiding those leading to unwanted side effects such as the arrestin protein signalling pathway that mediates receptor desensitization and analgesic tolerance and possibly proconvulsant activity. PN6047 can be the first of a new drug class for neuropathic pain treatment - delta opioid-biased receptor agonists (DOBRAs). Preclinical studies have shown that PN6047 is safe, tolerable and effective in treating neuropathic pain and also other pain-related indications such as opioid withdrawal and chronic cough. The clinical Phase I study has confirmed that PN6047 is safe and tolerable at doses predicted to be efficacious. Now the drug is ready to proceed into a Phase IIa PoC study, which is the focus of the proposed Accelerator project. The confirmation of the clinical efficacy of PN6047 will enable us to enter an out-licensing agreement with one of the major players in the chronic pain market. Alternatively, it would allow us to attract significant equity investments and finance subsequent Phase IIb and III clinical trials, scale up manufacturing, market approval and product launch. This project is of strategic health-economic importance for Europe. About 149 million people in Europe suffer from chronic pain including about 29.8 million neuropathic pain patients. In Europe, the healthcare cost of chronic pain is estimated at over €300bn annually (around 1.5% – 3% of GDP).

Keywords: chronic pain,neuropathic pain,delta opioid receptor agonist,biased signalling,delta opioid biased receptor agonist
SpatioTemporal Diversification of Enteric Nervous system (DeSTENy)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Sweden
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-09-01
End date: 2027-08-31
Duration (months): 24.0
Total project cost (EUR): 222727.68
EU funding (EUR): 222727.68
Participants: 1
Project status: SIGNED

The enteric nervous system (ENS) contains an extensive range of neural subtypes that collectively control essential gut functions largely independent of the central nervous system (CNS). Enteric neuronal diversity is critical for maintaining normal gut function, and a selective dysfunction or local neuronal loss leads to gastrointestinal (GI) disorders. As current treatments of ENS-related disorders are suboptimal, development of novel regenerative approaches has the potential to significantly improve GI health for millions worldwide. As a first milestone towards cell-based regenerative therapies, the Marklund lab recently established a molecular classification of intestinal enteric neurons and discovered that they diversify through a conceptually new stepwise principle during development. The proposed project, DeSTENy, will significantly expand on these discoveries, and investigate how time and spatial context of developing GI tract controls the developing ENS to acquire the appropriate neuron identities at the right time and region within the mouse gut. DeSTENy will integrate cutting-edge regular and spatial single-cell transcriptomics to identify potentially important spatiotemporal driver genes in the ENS of the intestine versus stomach and oesophagus (upper GI-tract). While studies of the developing ENS has been challenged by its inaccessible location within the gut wall, DeSTENy will overcome this limitation by the utilization a precise, rapid and large-scale gene manipulation strategy based on ultrasound-guided transduction of ENS precursor cells followed by temporally controlled gene expression. Apart from transforming our understanding of the largest division of the peripheral nervous system and fundamental developmental processes, DeSTENy will open avenues for regenerative medicine in treating neurological gut disorders, in particular the many affecting the upper GI-tract.

Keywords: enteric nervous system,developmental biology,inutero gene manipulation,viral transgenics,neural crest,cell fate diversification,neurogenesis,single cell transcriptomics
Collective Dark States of Atoms in Optical Cavities (Dark Cavities)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Denmark
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-06-01
End date: 2025-12-31
Duration (months): 31.0
Total project cost (EUR): 230774.4
EU funding (EUR): 230774.4
Participants: 1
Project status: SIGNED

The use of large ensembles of two-level atoms (qubits) in cavity QED allows the exploration of collective states with long-range couplings mediated by the electromagnetic field of the cavity. Such systems are interesting quantum sensors and can be used to improve the performance of lasers and atomic clocks in addition to studying fundamental quantum mechanical behaviors. However, this approach limits the possibilities of exploration to collective qubit behavior, whilst much more rich physics can be explored if one allows for the use of multi-level atoms (qudits). In this project I will use cold atoms coupled to optical cavities in order to generate entangled dark collective states in many-level atoms. Such dark collective states can be accessed via superradiant decay and may be used to enhance some quantum sensors. In addition they are of interest to quantum simulations to simulate topological systems and to quantum computation as temporary memories. I will demonstrate the experimental realization of theoretically proposed many-level dark states for quantum simulations and controlled coherence lifetimes.

Keywords: quantum simulation,quantum sensors
Cell Rejuvenation Therapy for Age-related Macular Degeneration (I-SEE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Israel
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-06-01
End date: 2023-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Age-related macular degeneration (AMD) is a leading cause for blindness, resulting in loss of vision at the center of the visual field - the macula, due to damage to the retina. The disease, usually affecting older adults (>55), was diagnosed in 2020 in 196 million people worldwide, with an estimated economic toll of $343 billion including $255 billion in direct healthcare costs. In AMD, photoreceptors and retinal pigmented epithelium (RPE) cells which underlie the photoreceptors undergo degeneration. The standard care is injections of anti-VEGF medicines such as ranibizumab (Lucentis), aflibercept (Eylea) and brolucizumab (Beovu) to the eye every 1-3 months. These delay disease progress but cannot restore lost vision, and have side effects such as bleeding in the eye. During an ERC Starting project, the PI has discovered a new method that would allow to not only delay the disease but to also improve RPE cells function as a treatment for AMD. The proposed approach to rescue RPE cells is rejuvenation by a technique called partial reprogramming. Our results suggest that the proposed technique is safe and efficient in rejuvenating mouse and human fibroblasts, and in improving their function. In the current application, through in vivo studies, we will prepare for implementing our novel approach in our envisioned product “I-SEE”. In “I-SEE”, we will aim to use our discovery of a unique combination of factors, that successfully reprogram cells, to drive aging RPE cells into rejuvenation and improved function. We will calibrate the expression of the reprogramming factors in RPE cells, and test rejuvenation and improved function in AMD mouse models. IPR and partnering with clinician and industry will be developed concomitantly. Our final product, “I-SEE”, is developed based on a PCT patent Application No. 63/210,030, as a cocktail of molecules of mRNA directly applied to the eye, to offer the first AMD treatment that could restore vision.